X0306 4 2019-02-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001238408 SUVARI TRICIA BORGA C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Legal Officer Common Stock 2019-02-01 4 M 0 3250 A 11526 D Common Stock 2019-02-01 4 F 0 1241 48.44 D 10285 D Stock Option (Right to Buy) 48.44 2019-02-01 4 A 0 40000 0.00 A 2029-01-31 Common Stock 40000 40000 D Restricted Stock Units 2019-02-01 4 A 0 25000 0.00 A Common Stock 25000 25000 D Restricted Stock Units 2019-02-01 4 M 0 3250 0.00 D Common Stock 3250 19500 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,250 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Lesley Ann Calhoun, as Attorney-in-Fact 2019-02-05